Himanshu Tandon, MD
Cardiovascular Disease · Waterloo, IANPI 1952501918
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $4,448 of the $6,969 with a category attached, or 63.8%. 8 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 49.5% of the total. Reporting peaked in 2019 at $2,205 and has fallen 95.4% since, to $102 in 2025.
Across 83 payments — averaging $83.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$3K
- Abbott$2K
- Medical Device Business Services, Inc.$702
- Medtronic$489
- Boston Scientific$73
- Philips North America LLC$70
- plus $84 from 2 others
What the payments were for
- Travel & lodging$4,44864%
- Food & beverage$2,52136%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 26 | $3,451 |
| Abbott | 16 | $2,099 |
| Medical Device Business Services, Inc. | 7 | $702 |
| Medtronic(2 entities) | 28 | $489 |
| Boston Scientific | 3 | $73 |
| Philips North America LLC | 1 | $70 |
| Livanova USA, Inc. | 1 | $59 |
| Teleflex LLC | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,969 in reported general payments places this provider in the 85th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 513 | $498,964 |
| XareltoRivaroxaban | 486 | $478,322 |
| JardianceEmpagliflozin | 154 | $153,803 |
| EntrestoSacubitril/Valsartan | 35 | $28,781 |
| FarxigaDapagliflozin Propanediol | 36 | $21,070 |
| Repatha SureclickEvolocumab | 26 | $16,511 |
| Metoprolol Succinate | 1,211 | $13,743 |
| BrilintaTicagrelor | 18 | $13,586 |
| Droxidopa | 16 | $6,669 |
| Ranolazine ErRanolazine | 57 | $5,215 |
| Flecainide Acetate | 129 | $5,035 |
| Rosuvastatin Calcium | 529 | $4,720 |
| Torsemide | 229 | $4,252 |
| Atorvastatin Calcium | 476 | $4,218 |
| Furosemide | 645 | $4,169 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Waterloo
- Richard ValenteWaterloo$3K
- Brian OlshanskyIowa City$219K
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Gursukhman Deep SidhuDavenport$60K
- Suzanne FeigofskyWest Des Moines$59K
- Tyler RasmussenCedar Rapids$37K
- Jennifer RobinsonIowa City$37K
- Matthew McMahonCedar Rapids$35K
- Craig StarkDes Moines$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.